In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Ventriculoarterial coupling and myocardial deformation parameters in patients with functional mitral regurgitation and normal controls: a cardiac magnetic resonance study

Session Poster session 2

Speaker Max Eitan Godfrey

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Deformation Imaging
  • Session type : Poster Session

Authors : M E Godfrey (Jerusalem,IL), D Mann (Jerusalem,IL), T Hasin (Jerusalem,IL), N Bogot (Jerusalem,IL), A Shalev (Beer Sheva,IL), M Glikson (Jerusalem,IL), A Wolak (Jerusalem,IL)

M E Godfrey1 , D Mann1 , T Hasin1 , N Bogot1 , A Shalev2 , M Glikson1 , A Wolak1 , 1Shaare Zedek Medical Center - Jerusalem - Israel , 2Soroka University Medical Center - Beer Sheva - Israel ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii350

The ventriculoarterial coupling (VAC) ratio, the ratio of arterial and ventricular elastance, is a measure of cardiovascular efficiency, and can be estimated non-invasively as the ratio of end-systolic volume to stroke volume. Little is known about the potential relationship between VAC and myocardial deformation. We used a previously-described cardiac magnetic resonance (CMR) method to assess VAC in a cohort of patients with functional mitral regurgitation (FMR), examined its relation to myocardial deformation variables, and compared with controls.


To calculate VAC and myocardial deformation variables in a cohort of patients with FMR, as compared with normal controls, using CMR, and assess for correlation.

We analysed CMR data from a cohort of patients with FMR with a mitral regurgitation fraction >10% (n=41), as well as controls with normal cardiac anatomy and function (n=49). All subjects underwent CMR studies for clinical indications. 2D myocardial-tracking analyses were conducted using commercially available software. We calculated VAC (end-systolic volume/stroke volume), peak apical displacement (PAD), peak basal displacement (PBD), global longitudinal strain (GLS), longitudinal displacement (GLD) and ventricular twist.

The median age of the control cohort was 42.5 years, range 16-78 years, and 63% were male. The median age of the FMR cohort was 57 years old, range 23-84 years, and 66% were male (p=0.0005 for age). Patients with FMR had significantly increased median VAC as compared to controls (1.85 vs 0.59, p<0.0001, figure A), with a "dose-dependent" increase in VAC observed with increasing regurgitation fraction (p=0.0145, R²=0.144, figure B). Twist, GLD and GLS correlated negatively with VAC in the FMR cohort, with GLS showing the strongest correlation (p<0.0001, R²=0.59, figure C), but only GLS correlated with VAC in the control cohort. There was no significant correlation between VAC and PAD or PBD, and there was no significant correlation between VAC and age.

Although the control cohort was significantly younger, the absence of a correlation between VAC and age in this study suggest that the results should not be affected by this. We found that patients with FMR demonstrate cardiovascular inefficiency as evidenced by increased VAC ratio and this correlates with myocardial deformation parameters, in particular GLS. We found a relationship between GLS and VAC in both FMR and control subjects. Further study into the relationship between these parameters is warranted, in particular to assess the possible prognostic implications.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are